Showing results (111-120 of 127) with videos related to
Sort By:
Pageof 13
FEBS Letters|November 24, 2016
Discovery and biological characterization of potent myeloid cell leukemia-1 inhibitorsTaekyu Lee, Zhiguo Bian, Bin Zhao, et al.Cancer Cell|July 24, 2018
MAST1 Drives Cisplatin Resistance in Human Cancers by Rewiring cRaf-Independent MEK ActivationLingtao Jin, Jaemoo Chun, Chaoyun Pan, et al.The Journal of Clinical Investigation|August 1, 2023
Regulation of antigen-specific T cell infiltration and spatial architecture in multiple myeloma and premalignancyM Hope Robinson, Nancy Y Villa, David L Jaye, et al.Cell Metabolism|January 17, 2017
Prevention of Dietary-Fat-Fueled Ketogenesis Attenuates BRAF V600E Tumor GrowthSiyuan Xia, Ruiting Lin, Lingtao Jin, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 13, 2021
Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone With Minimal Residual Disease Response-Adapted Therapy in Newly Diagnosed Multiple MyelomaLuciano J Costa, Saurabh Chhabra, Eva Medvedova, et al.American Journal of Hematology|June 22, 2022
Impact of autologous hematopoietic cell transplantation on disease burden quantified by next-generation sequencing in multiple myeloma treated with quadruplet therapySusan Bal, Binod Dhakal, Rebecca W Silbermann, et al.The Lancet. Haematology|September 30, 2023
Minimal residual disease response-adapted therapy in newly diagnosed multiple myeloma (MASTER): final report of the multicentre, single-arm, phase 2 trialLuciano J Costa, Saurabh Chhabra, Eva Medvedova, et al.Blood|January 2, 2026
Genomic mechanisms of resistance to venetoclax in multiple myeloma with t(11;14)(CCND1;IGH)Marcella Kaddoura, Julia Erin Wiedmeier-Nutor, Vikas A Gupta, et al.Nature Medicine|January 15, 2026
Multimodal antigenic escape to GPRC5D-targeted T cell engagers in multiple myelomaHolly Lee, Sungwoo Ahn, Gerone A Gonzales, et al.Biorxiv : the Preprint Server for Biology|March 11, 2024
Targeting high-risk multiple myeloma genotypes with optimized anti-CD70 CAR-T cellsCorynn Kasap, Adila Izgutdina, Bonell Patiño-Escobar, et al.Pageof 13